cfMSC Stem Cell Therapy Targeting COPD

Other illness

• Combined with other serious lung diseases: asthma, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism, interstitial lung disease, pulmonary hypertension, etc.;
• A history of lung surgery (pneumonectomy, lung volume reduction surgery, etc.) or bronchial intervention surgery within 12 months;
• Negative for HIV, HCV or syphilis serology;
• A history of malignant tumors or malignant tumors under treatment;
• Autoimmune diseases requiring long-term use of glucocorticoids or immunosuppressants;
• A history of alcohol or drug abuse, or mental diseases that cannot cooperate with the study;

Lab values

• Poorly controlled diabetes (fasting blood glucose \> 10.0 mmol/L) or severe metabolic diseases;

Other

• Invasive or non-invasive mechanical ventilation history within 4 weeks, or moderate to severe acute exacerbation of COPD within 4 weeks;
• Pregnancy or breastfeeding.
• Unable or unwilling to comply with study specific schedules or procedures.

• Ability to understand the study protocol and the willingness to provide written informed consent;
• Age 40-80 years old, male or female;
• Diagnosed with moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD Ⅱ-Ⅳ).
• Regular use of COPD conventional drugs for more than 3 months, and the condition is stable for more than 4 weeks;
• ineffective clinical treatment;
• Life expectancy \> 6 months;
• At least six months smoking cessation, including non-smoking during the treatment and follow-up periods of the study.